Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging
- PMID: 2326475
- DOI: 10.1148/radiology.175.2.2326475
Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging
Abstract
An ultrasmall superparamagnetic iron oxide (USPIO) preparation was evaluated as a potential intravenous contrast agent for lymph nodes. Relaxation time measurements and magnetic resonance (MR) imaging were performed in rats with normal lymph nodes and in rats with lymph node metastases. In normal animals, lymph node relaxation times decreased maximally within 24-48 hours after intravenous administration of USPIO. Twenty-four hours after administration, the T2 of normal lymph nodes had decreased from 74 msec +/- 2.2 to 30 msec +/- 0.7 (USPIO, 40 mumol of iron per kilogram) or 15 msec +/- 0.0 (200 mumol Fe/kg), whereas the T2 of metastatic nodes did not change. MR imaging of the animal model of nodal metastases confirmed the hypothesis that intravenously administered USPIO decreases signal intensity of normal but not metastatic nodes. A single intravenous administration of USPIO may allow detection of nodal metastases on the basis of signal intensity characteristics rather than the currently used, insensitive size characteristics.
Similar articles
-
Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging.Radiology. 1990 May;175(2):489-93. doi: 10.1148/radiology.175.2.2326474. Radiology. 1990. PMID: 2326474
-
Lymph nodes: microstructural anatomy at MR imaging.Radiology. 1991 Feb;178(2):519-22. doi: 10.1148/radiology.178.2.1987619. Radiology. 1991. PMID: 1987619
-
Experimental lymph node metastases: enhanced detection with MR lymphography.Radiology. 1989 Jun;171(3):835-9. doi: 10.1148/radiology.171.3.2717761. Radiology. 1989. PMID: 2717761
-
Use of ultrasmall superparamagnetic iron oxide in lymph node MR imaging in prostate cancer patients.Eur J Radiol. 2007 Sep;63(3):369-72. doi: 10.1016/j.ejrad.2007.06.025. Epub 2007 Aug 6. Eur J Radiol. 2007. PMID: 17689215 Review.
-
The pharmacokinetics of the lymphotropic nanoparticle MRI contrast agent ferumoxtran-10.Cancer Biomark. 2009;5(2):69-73. doi: 10.3233/CBM-2009-0579. Cancer Biomark. 2009. PMID: 19414923 Review.
Cited by
-
The effects of magnetite (Fe₃O₄) nanoparticles on electroporation-induced inward currents in pituitary tumor (GH₃) cells and in RAW 264.7 macrophages.Int J Nanomedicine. 2012;7:1687-96. doi: 10.2147/IJN.S28798. Epub 2012 Mar 27. Int J Nanomedicine. 2012. PMID: 22615532 Free PMC article.
-
Accuracy of computed tomography and magnetic resonance imaging in the detection of lymph node involvement in cervix carcinoma.Eur Radiol. 2005 Dec;15(12):2469-74. doi: 10.1007/s00330-005-2847-1. Epub 2005 Jul 6. Eur Radiol. 2005. PMID: 15999213
-
Preparation and evaluation of poly(2-hydroxyethyl aspartamide)-hexadecylamine-iron oxide for MR imaging of lymph nodes.Nanoscale Res Lett. 2014 Jan 18;9(1):38. doi: 10.1186/1556-276X-9-38. Nanoscale Res Lett. 2014. PMID: 24438671 Free PMC article.
-
Ferumoxytol-enhanced MR imaging for differentiating intrapancreatic splenules from other tumors.Abdom Radiol (NY). 2021 May;46(5):2003-2013. doi: 10.1007/s00261-020-02883-y. Epub 2020 Dec 30. Abdom Radiol (NY). 2021. PMID: 33377995 Free PMC article.
-
Lymph node imaging in initial staging of prostate cancer: An overview and update.World J Radiol. 2017 Oct 28;9(10):389-399. doi: 10.4329/wjr.v9.i10.389. World J Radiol. 2017. PMID: 29104741 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical